glp 1 winner Amanda Bonello interviews Sabina Hemmi, founder of Winner, about the Safe Drugs Act and state bills threatening compounded GLP-1 access, including semaglutide and tirzepatide, and what patients can do to protect muscle loss GLP Winner | LinkedIn

Recent Findings GLP-1RA therapy maintains receptor signaling while reducing nutrient inflow, creating a physiological state of chronic energy flux constriction

The researchers scoured an enzyme database and identified the kumamolisin-As peptidase from Alicyclobacillus sendaiensis , a bacterium that thrives in acidic soil, as their template

Similarly, reductions in tryptophan-metabolizing bacteria (e.g., Clostridium sporogenes and Bacteroides ) lower levels of indole-3aldehyde and other AHR ligands, impairing skin barrier repair and immune regulation

As such, ALCAR is considered a more potent alternative to L-Carnitine